Trending NewsTrending NewsNASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $0.22 0.00 (-0.95%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$0.22 0.00 (-1.33%) As of 09:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Gossamer Bio Stock (NASDAQ:GOSS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gossamer Bio alerts:Sign Up Key Stats Today's Range$0.20▼$0.2350-Day Range$0.19▼$0.4752-Week Range$0.16▼$3.87Volume16.09 million shsAverage Volume10.53 million shsMarket Capitalization$51.14 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need. The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies. In addition to these clinical-stage assets, Gossamer Bio maintains several earlier-stage programs targeting pathways such as integrin and TGF-β signaling. The company’s R&D efforts are supported by a combination of in-house research capabilities and external collaborations with academic centers and contract research organizations. Gossamer Bio completed its initial public offering in July 2019 and has since advanced multiple clinical trials across North America and selected international sites. The company is led by President and Chief Executive Officer Thomas A. Whiting, a veteran of the biopharmaceutical industry with over 25 years of drug development experience. Under his leadership, Gossamer Bio continues to build a multidisciplinary management team focused on accelerating the translation of scientific insights into therapeutic candidates.AI Generated. May Contain Errors. Read More Gossamer Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreGOSS MarketRank™: Gossamer Bio scored higher than 50% of companies evaluated by MarketBeat, and ranked 548th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingHold Consensus RatingGossamer Bio has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 4 buy ratings, 4 hold ratings, and 2 sell ratings.Upside PotentialGossamer Bio has a consensus price target of $5.00, representing about 2,194.6% upside from its current price of $0.22.Amount of Analyst CoverageGossamer Bio has only been the subject of 4 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gossamer Bio are expected to grow in the coming year, from ($0.47) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Gossamer Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.75% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 11.48, which indicates bearish sentiment.Change versus previous monthShort interest in Gossamer Bio has recently increased by 2.05%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.08 News SentimentGossamer Bio has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Gossamer Bio this week, compared to 7 articles on an average week.Search Interest11 people have searched for GOSS on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat Follows4 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by Insiders7.20% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GOSS Stock News HeadlinesGOSS 4-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS19 minutes ago | prnewswire.comGOSSAMER DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSSMay 27 at 8:15 PM | globenewswire.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.May 28 at 1:00 AM | Porter & Company (Ad)Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSSMay 27 at 7:54 PM | globenewswire.comDEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersMay 27 at 12:07 PM | globenewswire.comGossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitMay 27 at 12:00 PM | prnewswire.comGOSS INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the June 1, 2026 Lead Plaintiff Deadline in the Gossamer Bio, Inc. Securities Class ActionMay 27 at 8:00 AM | globenewswire.comGOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 27 at 3:42 AM | prnewswire.comSee More Headlines GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $3.10 at the beginning of 2026. Since then, GOSS shares have decreased by 93.0% and is now trading at $0.2179. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) released its quarterly earnings results on Monday, May, 18th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.03. The company had revenue of $16.96 million for the quarter, compared to the consensus estimate of $4.67 million. Read the conference call transcript. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. Who are Gossamer Bio's major shareholders? Gossamer Bio's top institutional investors include Kalehua Capital Management LLC (4.36%), Octagon Capital Advisors LP (3.30%), Bank of America Corp DE (1.35%) and Rock Springs Capital Management LP (0.69%). Insiders that own company stock include Faheem Hasnain, Richard Aranda and Bryan Giraudo. View institutional ownership trends. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/18/2026Today5/28/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 GOSS's financial health is in the Red zone, according to TradeSmith. GOSS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOSS CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees180Year Founded2015Price Target and Rating Average Price Target for Gossamer Bio$5.00 High Price Target$11.00 Low Price Target$1.00 Potential Upside/Downside+2,194.6%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$170.37 million Net Margins-324.82% Pretax Margin-324.98% Return on EquityN/A Return on Assets-96.10% Debt Debt-to-Equity RatioN/A Current Ratio2.20 Quick Ratio2.20 Sales & Book Value Annual Sales$48.47 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / Book-0.32Miscellaneous Outstanding Shares234,700,000Free Float217,798,000Market Cap$51.14 million OptionableOptionable Beta2.15 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:GOSS) was last updated on 5/28/2026 by MarketBeat.com Staff. From Our PartnersWall Street’s $3.3B critical mineral darling just got spanked by a $300M junior …NevGold Corp. (OTCQX: NAUFF) just released drill results showing up to 53.71% antimony - potentially one of th...i2i Marketing Group, LLC | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're not telling you how bad this could getValuations are stretched to levels seen only a handful of times in the last hundred years — yet most retiremen...Parkview Capital Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
